CASP3 and cancer: The expression level of C-myc and mitochondrial hexokinase II was suppressed in cancer cells treated with triptolide, which would accelerate mitochondrial translocation of BAD/BAX, leading to caspase-3 activation, GSDME cleavage, IL-1β, and LDH1 release, and pyroptosis ultimately.